Raph Leonardus Hamers

Raph Leonardus Hamers

Auto-generated profile, based on publicly available information

Raph Leonardus Hamers

Oxford University Clinical Research Unit Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2024 in The Lancet Microbe
Verified
Journal Article
Open access
SBSilvia Bertagnolio
Silvia Bertagnolio
ZDZlatina Dobreva
Zlatina Dobreva
CCChad M Centner
Chad M Centner
IOIoana Diana Olaru
Ioana Diana Olaru
DDDaniele Donà
Daniele Donà
WCWHO Research Agenda for AMR in Human Health Collaborators
WHO Research Agenda for AMR in Human Health Collaborators
The WHO research agenda for antimicrobial resistance (AMR) in human health has identified 40 research priorities to be addressed by the year 2030. These priorities focus on bacterial and fungal pathogens of crucial importance in addressing AMR, including drug-resistant pathogens causing tuberculosis. These research priorities encompass the entire people-centred journey, covering prevention, diagnosis, and treatment of antimicrobial-resistant infections, in addition to addressing the overarching knowledge gaps in AMR epidemiology, burden and drivers, policies and regulations, and awareness and education. The research priorities were identified through a multistage process, starting with a comprehensive scoping review of knowledge gaps, with expert inputs gathered through a survey and open call. The priority setting involved a rigorous modified Child Health and Nutrition Research Initiative approach, ensuring global representation and applicability of the findings. The ultimate goal of this research agenda is to encourage research and investment in the generation of evidence to better understand AMR dynamics and facilitate policy translation for reducing the burden and consequences of AMR.

1 April 2021 in The Lancet Regional Health - Western Pacific
Verified
Journal Article
Open access
HSHenry Surendra
Henry Surendra
IEIqbal Rf Elyazar
Iqbal Rf Elyazar
BDBimandra A Djaafara
Bimandra A Djaafara
LELenny L Ekawati
Lenny L Ekawati
KSKartika Saraswati
Kartika Saraswati
RHRaph L. Hamers
Raph L. Hamers
Data on COVID-19-related mortality and associated factors from low-resource settings are scarce. This study examined clinical characteristics and factors associated with in-hospital mortality of COVID-19 patients in Jakarta, Indonesia, from March 2 to July 31, 2020. This retrospective cohort included all hospitalised patients with PCR-confirmed COVID-19 in 55 hospitals. We extracted demographic and clinical data, including hospital outcomes (discharge or death). We used logistic regression to examine factors associated with mortality. Of 4265 patients with a definitive outcome by July 31, 3768 (88%) were discharged and 497 (12%) died. The median age was 46 years (IQR 32–57), 5% were children, and 31% had >1 comorbidity. Age-specific mortalities were 11% (7/61) for 3) symptoms; immediate ICU admission, or intubation. Across all ages, risk of death was higher for patients with >1 comorbidity compared to those without; notably the risk was six-fold increased among patients 10% mortality among children 50 years.

1 October 2018 in The Lancet HIV
Verified
Journal Article
Closed access
RHRaph L Hamers
Raph L Hamers
TWTobias F Rinke de Wit
Tobias F Rinke de Wit
CHCharles B Holmes
Charles B Holmes

25 May 2022 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
RLRalalicia Limato
Ralalicia Limato
GLGilbert Lazarus
Gilbert Lazarus
PDPuck Dernison
Puck Dernison
MMManzilina Mudia
Manzilina Mudia
MAMonik Alamanda
Monik Alamanda
RHRaph L. Hamers
Raph L. Hamers
A major driver of antimicrobial resistance (AMR) and poor clinical outcomes is suboptimal antibiotic use, although data are lacking in low-resource settings. We reviewed studies on systemic antibiotic use (WHO ATC/DDD category J01) for human health in Indonesia, and synthesized available evidence to identify opportunities for intervention. We systematically searched five international and national databases for eligible peer-reviewed articles, in English and Indonesian, published between 1 January 2000 and 1 June 2021 including: (1) antibiotic consumption; (2) prescribing appropriateness; (3) antimicrobial stewardship (AMS); (4) consumers’ and providers’ perceptions. Two independent reviewers included studies and extracted data. Study-level data were summarized using random-effects model meta-analysis for consumption and prescribing appropriateness, effect direction analysis for antimicrobial stewardship (AMS) interventions, and qualitative synthesis for perception surveys. (PROSPERO: CRD42019134641) Of 9323 search hits, we included 100 reports on antibiotic consumption (20), prescribing appropriateness (49), AMS interventions (13), and/or perception (25) (8 categorized in >1 domain). The pooled estimate of overall antibiotic consumption was 134.8 DDD per 100 bed-days (95%CI 82.5–187.0) for inpatients and 121.1 DDD per 1000 inhabitants per day (10.4-231.8) for outpatients. Ceftriaxone, levofloxacin, and ampicillin were the most consumed antibiotics in inpatients, and amoxicillin, ciprofloxacin, and cefadroxil in outpatients. Pooled estimates for overall appropriate prescribing (according to Gyssens method) were 33.5% (18.1–53.4) in hospitals and 49.4% (23.7–75.4) in primary care. Pooled estimates for appropriate prescribing (according to reference guidelines) were, in hospitals, 99.7% (97.4–100) for indication, 84.9% (38.5-98.0) for drug choice, and 6.1% (0.2–63.2) for overall appropriateness, and, in primary care, 98.9% (60.9-100) for indication, 82.6% (50.5–95.7) for drug choice and 10.5% (0.8–62.6) for overall appropriateness. Studies to date evaluating bundled AMS interventions, although sparse and heterogeneous, suggested favourable effects on antibiotic consumption, prescribing appropriateness, guideline compliance, and patient outcomes. Key themes identified in perception surveys were lack of community antibiotic knowledge, and common non-prescription antibiotic self-medication. Context-specific intervention strategies are urgently needed to improve appropriate antibiotic use in Indonesian hospitals and communities, with critical evidence gaps concerning the private and informal healthcare sectors. Wellcome Africa Asia Programme Vietnam.

27 June 2024 in Medical Mycology
Verified
Journal Article
Open access
PDF file
CMC Orla Morrissey
C Orla Morrissey
HKHannah Y Kim
Hannah Y Kim
TDTra-My N Duong
Tra-My N Duong
EMEric Moran
Eric Moran
Ana Alastruey-IzquierdoAna Alastruey-Izquierdo
Ana Alastruey-Izquierdo
JBJustin Beardsley
Justin Beardsley
Recognizing the growing global burden of fungal infections, the World Health Organization established a process to develop a priority list of fungal pathogens (FPPL). In this systematic review, we aimed to evaluate the epidemiology and impact of invasive infections caused by Aspergillus fumigatus to inform the first FPPL. The pre-specified criteria of mortality, inpatient care, complications and sequelae, antifungal susceptibility, risk factors, preventability, annual incidence, global distribution, and emergence were used to search for relevant articles between 1 January 2016 and 10 June 2021. Overall, 49 studies were eligible for inclusion. Azole antifungal susceptibility varied according to geographical regions. Voriconazole susceptibility rates of 22.2% were reported from the Netherlands, whereas in Brazil, Korea, India, China, and the UK, voriconazole susceptibility rates were 76%, 94.7%, 96.9%, 98.6%, and 99.7%, respectively. Cross-resistance was common with 85%, 92.8%, and 100% of voriconazole-resistant A. fumigatus isolates also resistant to itraconazole, posaconazole, and isavuconazole, respectively. The incidence of invasive aspergillosis (IA) in patients with acute leukemia was estimated at 5.84/100 patients. Six-week mortality rates in IA cases ranged from 31% to 36%. Azole resistance and hematological malignancy were poor prognostic factors. Twelve-week mortality rates were significantly higher in voriconazole-resistant than in voriconazole-susceptible IA cases (12/22 [54.5%] vs. 27/88 [30.7%]; P = .035), and hematology patients with IA had significantly higher mortality rates compared with solid-malignancy cases who had IA (65/217 [30%] vs. 14/78 [18%]; P = .04). Carefully designed surveillance studies linking laboratory and clinical data are required to better inform future FPPL.

6 December 2019 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
NFNuno Rodrigues Faria
Nuno Rodrigues Faria
NVNicole Vidal
Nicole Vidal
José LourençoJosé Lourenço
José Lourenço
JRJayna Raghwani
Jayna Raghwani
KSKim C. E. Sigaloff
Kim C. E. Sigaloff
SDSimon Dellicour
Simon Dellicour
Since the ignition of the HIV-1 group M pandemic in the beginning of the 20th century, group M lineages have spread heterogeneously throughout the world. Subtype C spread rapidly through sub-Saharan Africa and is currently the dominant HIV lineage worldwide. Yet the epidemiological and evolutionary circumstances that contributed to its epidemiological expansion remain poorly understood. Here, we analyse 346 novel pol sequences from the DRC to compare the evolutionary dynamics of the main HIV-1 lineages, subtypes A1, C and D. Our results place the origins of subtype C in the 1950s in Mbuji-Mayi, the mining city of southern DRC, while subtypes A1 and D emerged in the capital city of Kinshasa, and subtypes H and J in the less accessible port city of Matadi. Following a 15-year period of local transmission in southern DRC, we find that subtype C spread at least three-fold faster than other subtypes circulating in Central and East Africa. In conclusion, our results shed light on the origins of HIV-1 main lineages and suggest that socio-historical rather than evolutionary factors may have determined the epidemiological fate of subtype C in sub-Saharan Africa. Since it emerged in human populations in the Democratic Republic of Congo (DRC) around 1920, HIV diversified in several virus lineages that spread across sub-Saharan Africa and beyond. While some lineages are rare and remain geographically confined to certain regions, e.g. subtypes H and J, others expanded rapidly across sub-Saharan Africa, e.g. subtype C. Here we conducted a spatial genetic analysis of the three main HIV-1 virus lineages, subtypes, A1, C and D, that co-circulate across 20 locations in central and East Africa, to investigate their spatial and temporal origins and their mode of spread across comparable geographic areas. We find that subtype C, currently the dominant lineage in sub-Saharan Africa, emerged in the southern DRC mining region, and spread 3-fold faster than other co-circulating lineages. Our study uncovers distinct patterns of spread of the main HIV-1 subtypes in a region that covers nearly half of all infected individuals in sub-Saharan Africa.